Radius Health Gets $43M to Push Osteo Injection, Patch
Radius Health Inc.'s new equity cash of $43 million will go toward further work with its anabolic bone builder BA058, in Phase III trials as an injectable therapy and Phase II as a "short-wear" patch.
Cash on hand with the latest financing "should take us neatly through the patch data [due in September], and then we'll make a decision on what the next steps are," said Michael Wyzga, president and CEO of Cambridge, Mass.-based Radius. Phase III data with the subcutaneous version will be available "on the back half of 2014," he said.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter